Genmab A/S’s (GMAB) “Buy” Rating Reiterated at HC Wainwright

Genmab A/S (NASDAQ:GMAB)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued on Thursday, Benzinga reports. They currently have a $50.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 93.80% from the company’s previous close.

Several other analysts have also recently commented on GMAB. Morgan Stanley reiterated an “underweight” rating on shares of Genmab A/S in a research report on Tuesday, March 26th. BMO Capital Markets raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and lifted their target price for the stock from $46.00 to $48.00 in a research note on Friday, February 23rd. Finally, Truist Financial increased their target price on shares of Genmab A/S from $50.00 to $53.00 and gave the company a “buy” rating in a research report on Tuesday, June 4th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Genmab A/S has a consensus rating of “Hold” and a consensus price target of $49.25.

Genmab A/S Stock Up 0.1 %

Shares of NASDAQ GMAB opened at $25.80 on Thursday. The firm has a market cap of $17.06 billion, a price-to-earnings ratio of 21.50, a price-to-earnings-growth ratio of 0.94 and a beta of 0.99. The company’s 50-day simple moving average is $28.43 and its 200-day simple moving average is $29.40. Genmab A/S has a 52-week low of $25.38 and a 52-week high of $42.72.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $0.16 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.16. Genmab A/S had a return on equity of 18.90% and a net margin of 30.74%. The company had revenue of $603.30 million for the quarter, compared to analysts’ expectations of $594.23 million. Equities research analysts anticipate that Genmab A/S will post 1.11 EPS for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

A number of institutional investors have recently bought and sold shares of the company. NewEdge Wealth LLC grew its stake in shares of Genmab A/S by 50.7% in the 4th quarter. NewEdge Wealth LLC now owns 119,989 shares of the company’s stock valued at $3,820,000 after buying an additional 40,382 shares during the period. Harding Loevner LP increased its stake in Genmab A/S by 2.7% during the fourth quarter. Harding Loevner LP now owns 3,289,895 shares of the company’s stock worth $97,569,000 after acquiring an additional 85,665 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Genmab A/S by 350.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,845 shares of the company’s stock worth $154,000 after acquiring an additional 3,770 shares during the last quarter. Northern Trust Corp raised its position in Genmab A/S by 83.3% in the third quarter. Northern Trust Corp now owns 559,044 shares of the company’s stock valued at $19,717,000 after purchasing an additional 254,042 shares during the period. Finally, Natixis Advisors L.P. lifted its stake in shares of Genmab A/S by 38.9% in the 3rd quarter. Natixis Advisors L.P. now owns 228,897 shares of the company’s stock valued at $8,073,000 after purchasing an additional 64,085 shares during the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.